Compare · NAUT vs RVTY
NAUT vs RVTY
Side-by-side comparison of Nautilus Biotechnology Inc. (NAUT) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAUT and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $12.29B, about 55.6x NAUT ($221.1M).
- Over the past year, NAUT is up 141.3% and RVTY is up 18.2% - NAUT leads by 123.1 points.
- NAUT has been more active in the news (7 items in the past 4 weeks vs 5 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 7 for NAUT).
PerformanceNAUT+141.27%RVTY+18.16%
2025-07-18+0.00%2026-07-17
- Company
- Nautilus Biotechnology Inc.
- Revvity Inc.
- Price
- $1.75+7.01%
- $110.22-1.29%
- Market cap
- $221.1M
- $12.29B
- 1M return
- -19.68%
- +8.84%
- 1Y return
- +141.27%
- +18.16%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 7
- 5
- Recent ratings
- 7
- 20
NAUT
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest NAUT
- Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 4 filed by Director Posard Matthew L.
- SEC Form 4 filed by Director Akinsanya Karen
- SEC Form 4 filed by Director Nazem Farzad
- SEC Form 4 filed by Director Mcilwain Matthew S
- SEC Form 4 filed by Director Epperly Melissa B,
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Large owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)
Latest RVTY
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026
- Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
- Bernstein resumed coverage on Revvity with a new price target
- SEC Form 11-K filed by Revvity Inc.
- Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
- Vice President and CAO Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.45% to 7,286 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)